Mobile

A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to th...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003656-35

A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to the last prior therapy for their disease

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy and safety of E7389 in patients with locally advanced or metastatic breast cancer who have received anthracycline, taxane, and capecitabine as prior therapy, and are refractory to their last chemotherapy regimen, documented by progression on or within six months of therapy.

Critère d'inclusion

  • Locally advanced or metastatic breast cancer

Liens